Dissolution Methods for Long-acting Periodontal Drug Products (U01)
There is a lack of compendial or biorelevant in vitro drug release assays for long-acting periodontal dosage forms. These products include biodegradable microspheres, in situ forming implants and matrix tablets. The purpose of this study is to develop a bio-relevant dissolution method for a long-acting periodontal dosage form and to identify the drug product's key physicochemical attributes that affect the drug dissolution behavior and bioavailability. The results from this study will help the FDA in developing recommendations to determine bioequivalence of generic long-acting periodontal drug products.
General information about this opportunity
Last Known Status
Deleted 05/27/2015 (Archived.)
Agency: Department of Health and Human Services
Office: Food and Drug Administration
Type(s) of Assistance Offered
Number of Awards Available
Who is eligible to apply/benefit from this assistance?
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are allowed.
What is the process for applying and being award this assistance?
Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements.
Who do I contact about this opportunity?
Grants Management Specialist
Range and Average of Financial Assistance
Awards up to $125,000.00